Effect of extremes of body weight on drug level in patient treated with standard dose of rivaroxaban for venous thromboembolism; real life experience

Thrombosis Research

Volumn 147, Issue , 2016, Pages 32-35

  Arachchillage, D R J ^a   Reynolds, R ^a   Devey, T ^a   Maclean, R ^a   Kitchen, S ^a   van Veen, J J ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Extremes of body weight; Rivaroxaban; Safety; Treatment outcome; Venous thromboembolism

Indexed keywords

CREATININE; RIVAROXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ADULT; AGED; BODY WEIGHT; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; CREATININE CLEARANCE; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RECURRENT DISEASE; UNITED KINGDOM; VENOUS THROMBOEMBOLISM; BLEEDING; CHEMICALLY INDUCED; COMPLICATION; LIFE EVENT; OBESITY; TREATMENT OUTCOME;

ADULT; AGED; BODY WEIGHT; FACTOR XA INHIBITORS; FEMALE; HEMORRHAGE; HUMANS; LIFE CHANGE EVENTS; MALE; MIDDLE AGED; OVERWEIGHT; RECURRENCE; RIVAROXABAN; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84988517596     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2016.09.010     Document Type: Letter

References (11)

1. [1] Baglin, T., Hillarp, A., Tripodi, A., Elalamy, I., Buller, H., Ageno, W., Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the subcommittee on control of anticoagulation of the scientific and standardisation committee of the international society on thrombosis and haemostasis. J. Thromb. Haemost. 11 (2013), 756–760.
2. [2] Kitchen, S., Gray, E., Mackie, I., Baglin, T., Makris, M., (Measurement of non-coumarin anticoagulants and their effects on tests of haemostasis: guidance from the British committee for standards in haematology. Br. J. Haematol. 166 (2014), 830–841.
3. [3] Martin, K., Beyer-Westendorf, J., Davidson, B.L., Huisman, M.V., Sandset, P.M., Moll, S., Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J. Thromb. Haemost.(14), 2016, 1–6.
4. [4] Prins, M.H., Nisio, M.D., Vedovati, M.C., Riera-Mestre, A., Mueller, K., Cohen, A.T., Wells, P.S., Beyer-Westendorf, J., Brighton, T.A., Bounameaux, H., Schneider, J., Lensing, A., Fixed-dose rivaroxaban is not associated with increased recurrent venous thromboembolism or major bleeding in patients with a high or low body weight. J. Thromb. Haemost. 13 (2015), 35–36.
5. [5] Dale, B.J., Ginsberg, J.S., Johnston, M., Hirsh, J., Weitz, J.I., Eikelboom, J.W., Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents. J. Thromb. Haemost. 12 (2014), 1810–1815.
6. [6] Schulman, S., Angeras, U., Bergqvist, D., Eriksson, B., Lassen, M.R., Fisher, W., (Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J. Thromb. Haemost. 8 (2010), 202–204.
7. [7] Bauersachs, R., Berkowitz, S.D., Brenner, B., Buller, H.R., Decousus, H., Gallus, A.S., Lensing, A.W., Misselwitz, F., Prins, M.H., Raskob, G.E., Segers, A., Verhamme, P., Wells, P., Agnelli, G., Bounameaux, H., Cohen, A., Davidson, B.L., Piovella, F., Schellong, S., (Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med. 363 (2010), 2499–2510.
8. [8] Buller, H.R., Prins, M.H., Lensin, A.W., Decousus, H., Jacobson, B.F., Minar, E., Chlumsky, J., Verhamme, P., Wells, P., Agnelli, G., Cohen, A., Berkowitz, S.D., Bounameaux, H., Davidson, B.L., Misselwitz, F., Gallus, A.S., Raskob, G.E., Schellong, S., Segers, A., (Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N. Engl. J. Med. 366 (2012), 1287–1297.
9. [9] Ageno, W., Mantovani, L.G., Haas, S., Kreutz, R., Monje, D., Schneider, J., EM, v., Gebel, M., Zell, E., Turpie, A.G., (Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol. 3 (2016), e12–e21.
10. [10] Eerenberg, E.S., Middeldorp, S., Levi, M., Lensing, A.W., Buller, H.R., (Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. J. Thromb. Haemost. 13 (2015), 1590–1596.
11. [11] Di Minno, M.N., Lupoli, R., Di, M.A., Ambrosino, P., Scalera, A., Dentali, F., (Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: a meta-analysis of randomized controlled trials. Ann. Med. 47 (2015), 61–68.